KALA BIO, Inc.

KALA

US4831192020

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:30:01 2024-04-26 pm EDT			5-day change	1st Jan Change
6.3 ^USD	+1.94%		-4.40%	-10.00%

Apr. 02	HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating	MT
Mar. 29	KALA BIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Health Care Down on Defensive Bias -- Health Care Roundup

December 30, 2022 at 05:28 pm EST

Health-care companies fell, but not by as much as the broad market, as the outperformance of defensive sectors continued.

Shares of Kala Pharmaceuticals continued to rally after receiving encouraging data on an eye-condition treatment.


 Write to Rob Curran at rob.curran@dowjones.com

(END) Dow Jones Newswires

12-30-22 1727ET

Latest news about KALA BIO, Inc.

HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating	Apr. 02	MT
KALA BIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
KALA BIO, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 29	CI
KALA BIO, Inc. announced that it expects to receive $8.599799 million in funding from Baker Bros. Advisors LP	Mar. 24	CI
North American Morning Briefing : Stocks Struggle After New Records	Mar. 22	DJ
North American Morning Briefing : Inflation -2-	Mar. 15	DJ
KALA BIO, Inc. announced that it expects to receive $1.999824 million in funding	Dec. 20	CI
HC Wainwright Adjusts Kala Pharmaceuticals Price Target to $22 From $24, Maintains Buy Rating	Nov. 17	MT
Wedbush Lowers Kala Pharmaceuticals' PT to $22 From $39, Moves US Launch Estimate for Lead Asset KPI-012; Maintains Outperform Rating	Nov. 14	MT
KALA BIO, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Wedbush Cuts Kala Pharmaceuticals' Price Target to $39 From $42, Maintains Outperform Rating	23-08-04	MT
KALA BIO, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-04	CI
Kala Pharmaceuticals Changes Name to Kala Bio	23-08-02	MT
Kala Pharmaceuticals, Inc. Announces Robert Paull Not Stands for Re-Election as A Director	23-05-11	CI
Kala Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Kala Pharmaceuticals Unit Secures $15 Million Grant from California Institute for Regenerative Medicine	23-04-28	MT
Kala Pharmaceuticals Shares Rise Nearly 5% After FDA Fast Track Designation	23-04-12	DJ
HC Wainwright & Co. Adjusts Price Target on Kala Pharmaceuticals to $22 From $20, Keeps Buy Rating	23-04-12	MT
Kala Pharmaceuticals, Inc. Appoints Francis Mah as Chief Medical Advisor	23-03-29	CI
Kala Pharmaceutical to Proceed with Corneal Epithelial Defect Trial After Positive Safety Data in Cohort 1	23-03-27	MT
Kala Pharmaceuticals, Inc. Announces Positive Safety Update from Cohort 1 of Chase Phase 2B Clinical Trial Evaluating KPI-012 in Patients with PCED	23-03-27	CI
Top Premarket Gainers	23-03-06	MT
HC Wainwright Adjusts Price Target on Kala Pharmaceuticals to $20 From $12, Keeps Buy Rating	23-03-06	MT
Wedbush Lowers Kala Pharmaceuticals' Price Target to $42 From $47 Due to Increased Share Count, Keeps Outperform Rating	23-03-06	MT
Kala Pharmaceuticals Files $350 Million Mixed Shelf, Files Shelf on Behalf of Selling Stockholders	23-03-06	MT

KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development and commercialization of therapies for rare and severe diseases of the eye. The Companyâs biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Companyâs product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived bio factors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its KPI-012 is used for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.3 USD

Average target price

19.33 USD

Spread / Average Target

+206.88%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
KALA BIO, INC.	-10.00%	17.74M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

KALA BIO, Inc.

Equities

KALA

US4831192020

Pharmaceuticals

Health Care Down on Defensive Bias -- Health Care Roundup

Latest news about KALA BIO, Inc.

Chart KALA BIO, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals